Study on anesthesia plan during gastroscopy in the elderly
Conditions
Interventions
PS Group:Propofol (1.0-1.5mg/kg)+sufentanil (0.5µg/kg)
RE Group:Remimazolam (0.2-0.3mg/kg)+Esketamine (0.2mg/kg)
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
60 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1) Elderly patients (aged 60-80) who plan to undergo painless gastroscopy for diagnosis and treatment, regardless of gender. 2) The subjects clearly understand and voluntarily participate in this study. 3) The informed consent form shall be signed by the subjects themselves and they shall voluntarily comply with the research process 4) ASA level I-II.
Exclusion criteria
Exclusion criteria: 1) According to the evaluation of the researchers, respiratory and/or pulmonary diseases that are not suitable for participation in the study include those who are expected to have difficulty intubating and those who suffer from sleep apnea syndrome; Patients with potentially life-threatening circulatory and respiratory diseases that have not been fully controlled. 2) Subjects who received general anesthesia within the first 7 days of randomization and those who received emergency treatment; 3) Have a history of tachycardia and/or severe arrhythmia; Patients with previous severe angina attacks, unstable angina or myocardial infarction in the past six months 4) Individuals with mental system disorders (such as schizophrenia, depression, etc.) and cognitive impairment; Having a history of epilepsy; Previous history of abuse of psychotropic and anesthetic drugs; Intracranial hypertension; 5) Hypertensive and hypotensive subjects who have not received formal antihypertensive treatment or have poor blood pressure control (screening period sitting systolic blood pressure = 180mmHg or = 90mmHg, and/or screening period diastolic blood pressure = 100mmHg or = 60mmHg); 6) People with severe liver and kidney dysfunction and poor control of diabetes 7) Clearly identify individuals who are allergic to the research medication.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| hypotension; | — |
Secondary
| Measure | Time frame |
|---|---|
| hypoxemia;hypertension;polycardia;bradycardia; | — |
Countries
China
Contacts
Public ContactWang Xiao
West China Hospital, Sichuan University
Outcome results
None listed